Your browser doesn't support javascript.
loading
Combining conventional therapy with immunotherapy: A risky business?
Coosemans, A; Vankerckhoven, A; Baert, T; Boon, L; Ruts, H; Riva, M; Blagden, S; Delforge, M; Concin, N; Mirza, M R; Ledermann, J A; du Bois, A; Vergote, I.
Affiliation
  • Coosemans A; Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. Electronic address: an.coosemans@kuleuven.be.
  • Vankerckhoven A; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. Electronic address: ann.vankerckhoven@kuleuven.be.
  • Baert T; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium; Kliniken Essen Mitte (KEM), Department of Gynaecology and Gynaecologic Oncology, Essen, Germany. Electronic address: T.Baert@kliniken-essen-mitte.de.
  • Boon L; Bioceros BV, Utrecht, the Netherlands. Electronic address: l.boon@bioceros.com.
  • Ruts H; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. Electronic address: hanne.ruts@hotmail.com.
  • Riva M; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium. Electronic address: matteo.riva@kuleuven.be.
  • Blagden S; Early Phase Clinical Trials Unit, Department of Oncology, University of Oxford, United Kingdom. Electronic address: sarah.blagden@oncology.ox.ac.uk.
  • Delforge M; Department of Haematology, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium. Electronic address: michel.delforge@uzleuven.be.
  • Concin N; Department of Gynaecology and Obstetrics, Medizinische Universität Innsbruck, Innsbruck, Austria. Electronic address: nicole.concin@i-med.ac.at.
  • Mirza MR; Rigshospitalet, Copenhagen University Hospital, Copenhagen, Denmark. Electronic address: Mansoor.Raza.Mirza@regionh.dk.
  • Ledermann JA; UCL Cancer Institute, University College London, London, United Kingdom. Electronic address: j.ledermann@ucl.ac.uk.
  • du Bois A; Kliniken Essen Mitte (KEM), Department of Gynaecology and Gynaecologic Oncology, Essen, Germany. Electronic address: prof.dubois@googlemail.com.
  • Vergote I; Department of Gynaecology and Obstetrics, Leuven Cancer Institute, UZ Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Tumour Immunology and Immunotherapy, ImmunOvar Research Group, KU Leuven, Leuven, Belgium; Department of Oncology, Laboratory of Gynecologic Oncology, KU Leuven, Leuve
Eur J Cancer ; 113: 41-44, 2019 05.
Article in En | MEDLINE | ID: mdl-30965214
ABSTRACT
Because of the failure of immunotherapy as single agent in a number of cancers, current clinical trials are focusing on combining immunotherapy with other therapies. The most frequently chosen combination for immunotherapy is chemotherapy. However, almost no preclinical data on this combination is available. Some studies even showed a dismal effect of combining chemotherapy with immunotherapy. Taken into account that each of the therapies chosen in a combination will influence the cancer cells but also immune effector cells as well as immunosuppressive cells, and that these three partners will also interact with each other, launching a combination to the patient without proper immune monitoring and preclinical evidence might be devastating.
Subject(s)
Key words
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents, Immunological / Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Cancer Year: 2019 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Antineoplastic Combined Chemotherapy Protocols / Antineoplastic Agents, Immunological / Neoplasms Type of study: Etiology_studies / Risk_factors_studies Limits: Humans Language: En Journal: Eur J Cancer Year: 2019 Document type: Article